Aspects of ischemic stroke biomechanics derived using ex-vivo and in-vitro methods relating to mechanical thrombectomy

2021 ◽  
pp. 110900
Author(s):  
Ray McCarthy ◽  
Mahmood Mirza ◽  
Sarah Johnson ◽  
Anushree Dwivedi ◽  
Gillian Gunning ◽  
...  
2020 ◽  
Vol 12 (10) ◽  
pp. 1002-1007
Author(s):  
Sarah Johnson ◽  
Ray McCarthy ◽  
Brian Fahy ◽  
Oana Madalina Mereuta ◽  
Seán Fitzgerald ◽  
...  

​BackgroundCalcified cerebral emboli (CCEs) are a rare cause of acute ischemic stroke (AIS) and are frequently associated with poor outcomes. The presence of dense calcified material enables reliable identification of CCEs using non-contrast CT. However, recanalization rates with the available mechanical thrombectomy (MT) devices remain low.ObjectiveTo recreate a large vessel occlusion involving a CCE using an in vitro silicone model of the intracranial vessels and to demonstrate the feasability of this model to test different endovascular strategies to recanalize an occlusion of the M1 segment of the middle cerebral artery (MCA).​MethodsAn in vitro model was developed to evaluate different endovascular treatment approaches using contemporary devices in the M1 segment of the MCA. The in vitro model consisted of a CCE analog placed in a silicone neurovascular model. Development of an appropriate CCE analog was based on characterization of human calcified tissues that represent likely sources of CCEs. Feasibility of the model was demonstrated in a small number of MT devices using four common procedural techniques.​ResultsCCE analogs were developed with similar mechanical behavior to that of ex vivo calcified material. The in vitro model was evaluated with various MT techniques and devices to show feasibility of the model. In this limited evaluation, the most successful retrieval approach was performed with a stent retriever combined with local aspiration through a distal access catheter, and importantly, with flow arrest and dual aspiration using a balloon guide catheter.​ConclusionCharacterization of calcified tissues, which are likely sources of CCEs, has shown that CCEs are considerably stiffer than thrombus. This highlights the need for a different in vitro AIS model for CCEs than those used for thromboemboli. Consequentially, an in vitro AIS model representative of a CCE occlusion in the M1 segment of the MCA has been developed.


2018 ◽  
Vol 46 (5-6) ◽  
pp. 270-278
Author(s):  
Jonathan Kottlors ◽  
Volker Maus ◽  
Anastasios Mpotsaris ◽  
Özgür A. Onur ◽  
Thomas Liebig ◽  
...  

Background: Ex vivo computed tomography (CT) studies of artificial blood thrombi showed that contrast enhancement (CE) is determined by fibrin-content, while unenhanced density is associated with red blood cells. Thus, the present study investigates patient outcome in association with combined thrombus density measures in native and contrast-enhanced CT (CECT) of acute ischemic stroke patients. Methods: This retrospective study includes 137 patients with M1 occlusions treated by mechanical thrombectomy (MT) between 2010 and 2016. Clinical outcome was determined with modified Rankin Scale (mRS) at 90 days. Differentiation of complete and incomplete large vessel occlusion (CLVO/ILVO) was based on CT and angiography. Two blinded readers classified blood thrombi based on native non-enhanced CT (NECT) as (a) hypo-, (b) iso-, and (c) hyperdense and in CECT angio measurements as (d) not-enhancing, (e) intermediate and (f) enhancing. To make sure that the mean is not represented in any of the maximum/minimum groups, thresholds in both cases were selected in a way that all values within one SD around the mean value form the isodense/intermediate group. In addition, the CE per se was correlated with the outcome. Correlations between imaging and clinical scales were performed with Spearman’s Rho. For the group testing Pearson chi-square test, Mann-Whitney U, as well parametric and nonparametric one-factor ANOVA “Kruskal-Wallis” test including Bonferroni correction for multiple tests ware used. Results: Twenty-three patients with ILVO (16.8%) differed significantly from patients with CLVO in mRS at admission (median 4 vs. 5) and after 90 days (median 1 vs. 4; p < 0.05) and thus were excluded. In the ILVO cohort, the classification according to NECT did not show statistical difference between hypo-, iso- and hyperdense CLVOs in regard to outcome. Classification of CLVOs according to CECT allowed an outcome prediction between the intermediate (median 3) and enhancing group (median 5) and between the enhancing and non-enhancing group (median 3; both p < 0.05) with a correlation of 291 between CE and higher mRS after 90 days (p < 0.005). Conclusions: CE of thrombi – especially in a range from over 18.4 to 40.35 Hounsfield Units – is an independent predictor of poor clinical outcome in patients undergoing MT due to acute middle cerebral artery occlusion.


Author(s):  
Juyu Chueh ◽  
Christine F. Silva ◽  
Ajay K. Wakhloo ◽  
Matthew J. Gounis

Mechanical thrombectomy devices, such as retrievers or aspiration catheters, have recently received approval from the FDA for the treatment of acute ischemic stroke. There is growing interest in endovascular recanalization procedures due to mounting evidence of favorable clinical outcomes. Several attempts have been made to establish dedicated clot models for in-vitro or in-vivo simulation of thromboembolism [1,2]. However, little is known about the mechanical and structural similarities between experimental clots and human sources of emboli that cause stroke. The goal of this study is to compare the structure and compression behavior of the possible sources of the cerebral emboli extracted from patients and model clots produced in-vitro using human, porcine and bovine donors.


Author(s):  
Maxim Mokin ◽  
Ana Martinez ◽  
Zackary Lorton ◽  
Julia Kretz ◽  
Chris Bashur ◽  
...  

Introduction : Ischemic stroke (IS) makes up a significant proportion of all strokes, of which large vessel occlusions (LVO) are the most debilitating type. The current clinical standard‐of‐care for IS includes mechanical thrombectomy with stent retrievers. One of the impediments to the success of SR intervention is endothelial injury (EI), which can occur in approximately 30% of cases and impedes vessel reperfusion. Since successful reperfusion of the occluded vessel is instrumental in survival and patient recovery, it is imperative to reduce device injury‐based complications such as vasospasm, and to improve patient outcomes. Methods : In this work, our hypothesis is that EI can be reduced by investigating the mechanisms of stent retriever‐induced injury in vitro using live cell 3D cerebrovascular models. Using true‐scale cerebrovascular phantoms with lumen diameter approximately 4 mm created using 3D printing and PDMS casting, Human Umbilical Vein Endothelial Cells (HUVECs) were seeded on the luminal surface. The in vitro models were coated with fibronectin (density 4 µgrams/cm2) to encourage cell adhesion, and were divided into control and treated samples (n = 3 each). Mechanical thrombectomy was performed using two different clinically used SR (Trevo XP PROVUE 3 × 20 mm and Trevo XP PROVUE 6 × 30 mm) to investigate the extent of stent retriever size on EI on the same diameter lumen. Following thrombectomy, the cerebrovascular models were fixed and stained with immunofluorescent dyes (DAPI, Phalloidin and VE cadherin antibody) and imaged using transmitted light, confocal microscopy and scanning electron microscopy. For quantitative assessment, real time PCR was performed on both control and treated samples. Results : All models were initially confluent and functional, as assessed by immunofluorescent staining (Figure 1 A and B). All treated samples demonstrated EI and endothelial damage, as evidenced by loss of endothelial cell coverage, denuding of the models, stripping / clumping of endothelial cells into non‐physiological three dimensional structures and physical scratching of the in vitro model (Figure 1 C and D). Sizing of stent retriever had a strong influence on the effects on the endothelium, with larger sizes causing more damage. Conclusions : A significant knowledge gap exists in understanding the factors responsible for disruption of the endothelium during mechanical thrombectomy. Using a 3D in vitro platform of cerebrovasculature, we demonstrated that endothelial damage occurs during thrombectomy using stent retrievers. A parameteric investigation is currently ongoing that characterizes the influence of vessel lumen diameter, stent retriever size, number of passes and patient specific vasculature. This work can provide guidelines for optimal stent retriever devices to be used where possible, ultimately reducing EI and improving outcomes of ischemic stroke treatment.


1997 ◽  
Vol 92 (s36) ◽  
pp. 4P-4P
Author(s):  
L.A. Thomas ◽  
G.M. Murphy ◽  
R.H. Dowling ◽  
A. King ◽  
G.R. French

Neurology ◽  
2019 ◽  
Vol 93 (18) ◽  
pp. e1686-e1698 ◽  
Author(s):  
Lucas Di Meglio ◽  
Jean-Philippe Desilles ◽  
Véronique Ollivier ◽  
Mialitiana Solo Nomenjanahary ◽  
Sara Di Meglio ◽  
...  

ObjectivesThrombi responsible for large vessel occlusion (LVO) in the setting of acute ischemic stroke (AIS) are characterized by a low recanalization rate after IV thrombolysis. To test whether AIS thrombi have inherent common features that limit their susceptibility to thrombolysis, we analyzed the composition and ultrastructural organization of AIS thrombi causing LVO.MethodsA total of 199 endovascular thrombectomy-retrieved thrombi were analyzed by immunohistology and scanning electron microscopy (SEM) and subjected to ex vivo thrombolysis assay. The relationship between thrombus organization and thrombolysis resistance was further investigated in vitro using thrombus produced by recalcification of citrated whole blood.ResultsSEM and immunohistology analyses revealed that, although AIS thrombus composition and organization was highly heterogeneous, AIS thrombi shared a common remarkable structural feature in the form of an outer shell made of densely compacted thrombus components including fibrin, von Willebrand factor, and aggregated platelets. In vitro thrombosis experiments using human blood indicated that platelets were essential to the formation of the thrombus outer shell. Finally, in both AIS and in vitro thrombi, the thrombus outer shell showed a decreased susceptibility to tissue plasminogen activator–mediated thrombolysis as compared to the thrombus inner core.InterpretationIrrespective of their etiology and despite their heterogeneity, intracranial thrombi causing LVO have a core shell structure that influences their susceptibility to thrombolysis.


Food systems ◽  
2018 ◽  
Vol 1 (3) ◽  
pp. 33-37
Author(s):  
Liliya V. Fedulova ◽  
Ekaterina R. Vasilevskaya ◽  
Elena A. Kotenkova ◽  
Elta B. Kashinova

The article describes in vitro methods basic principles, authors analyzed cell and tissue cultures used to assess toxicity and specific biological activity, including metabolic processes, include antihypertensive and cytoprotective properties analysis, antioxidant activity (in vitro and ex vivo) used to study ingredients functional properties based on animal origin raw materials, as well as meat products.


2021 ◽  
Vol 23 (1) ◽  
pp. 12-36
Author(s):  
Dmitri Nikitin ◽  
Seungbum Choi ◽  
Jan Mican ◽  
Martin Toul ◽  
Wi-Sun Ryu ◽  
...  

Despite recent advances in recanalization therapy, mechanical thrombectomy will never be a treatment for every ischemic stroke because access to mechanical thrombectomy is still limited in many countries. Moreover, many ischemic strokes are caused by occlusion of cerebral arteries that cannot be reached by intra-arterial catheters. Reperfusion using thrombolytic agents will therefore remain an important therapy for hyperacute ischemic stroke. However, thrombolytic drugs have shown limited efficacy and notable hemorrhagic complication rates, leaving room for improvement. A comprehensive understanding of basic and clinical research pipelines as well as the current status of thrombolytic therapy will help facilitate the development of new thrombolytics. Compared with alteplase, an ideal thrombolytic agent is expected to provide faster reperfusion in more patients; prevent re-occlusions; have higher fibrin specificity for selective activation of clot-bound plasminogen to decrease bleeding complications; be retained in the blood for a longer time to minimize dosage and allow administration as a single bolus; be more resistant to inhibitors; and be less antigenic for repetitive usage. Here, we review the currently available thrombolytics, strategies for the development of new clot-dissolving substances, and the assessment of thrombolytic efficacies <i>in vitro</i> and <i>in vivo</i>.


Sign in / Sign up

Export Citation Format

Share Document